Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.065.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.81% | -39.72% | -38.85% | -31.99% | -23.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.01% | -44.58% | -55.09% | -41.77% | -22.36% |
| Operating Income | 10.01% | 44.58% | 55.09% | 41.77% | 22.36% |
| Income Before Tax | 43.09% | 56.36% | 54.42% | 42.64% | -26.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.09% | 56.36% | 54.42% | 42.64% | -26.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.09% | 56.36% | 54.42% | 42.64% | -26.51% |
| EBIT | 10.01% | 44.58% | 55.09% | 41.77% | 22.36% |
| EBITDA | 7.57% | 45.36% | 56.10% | 42.77% | 22.73% |
| EPS Basic | 52.94% | 61.85% | 56.66% | 43.28% | -25.45% |
| Normalized Basic EPS | 24.66% | 61.88% | 56.65% | 46.02% | 33.09% |
| EPS Diluted | 52.94% | 61.85% | 56.76% | 43.31% | -25.45% |
| Normalized Diluted EPS | 24.66% | 61.88% | 56.65% | 46.02% | 33.09% |
| Average Basic Shares Outstanding | 20.93% | 14.41% | 5.17% | 1.14% | 0.85% |
| Average Diluted Shares Outstanding | 20.93% | 14.41% | 5.17% | 1.14% | 0.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |